Personal CFO Solutions LLC Reduces Holdings in STERIS plc $STE

Personal CFO Solutions LLC reduced its stake in shares of STERIS plc (NYSE:STE) by 48.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,873 shares of the medical equipment provider’s stock after selling 1,783 shares during the quarter. Personal CFO Solutions LLC’s holdings in STERIS were worth $450,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allworth Financial LP increased its position in shares of STERIS by 7.3% during the second quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 45 shares in the last quarter. Ashton Thomas Private Wealth LLC grew its stake in STERIS by 3.5% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 1,611 shares of the medical equipment provider’s stock worth $365,000 after buying an additional 54 shares during the last quarter. Cetera Investment Advisers increased its position in STERIS by 0.9% during the first quarter. Cetera Investment Advisers now owns 6,999 shares of the medical equipment provider’s stock worth $1,586,000 after buying an additional 63 shares during the period. Horizon Investments LLC increased its position in STERIS by 4.7% during the first quarter. Horizon Investments LLC now owns 1,410 shares of the medical equipment provider’s stock worth $320,000 after buying an additional 63 shares during the period. Finally, Alliance Wealth Advisors LLC UT lifted its stake in STERIS by 2.0% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,305 shares of the medical equipment provider’s stock valued at $749,000 after buying an additional 64 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at STERIS

In other news, CEO Daniel A. Carestio sold 159 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the sale, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at $12,356,034.72. This trade represents a 0.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the sale, the vice president owned 5,695 shares in the company, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 20,195 shares of company stock valued at $5,312,571. 1.07% of the stock is owned by corporate insiders.

STERIS Stock Performance

NYSE:STE opened at $263.34 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The firm has a market cap of $25.85 billion, a price-to-earnings ratio of 40.33 and a beta of 1.02. The firm’s fifty day moving average price is $246.90 and its 200 day moving average price is $241.41. STERIS plc has a 1-year low of $200.98 and a 1-year high of $268.30.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same quarter in the prior year, the firm earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, sell-side analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be given a $0.63 dividend. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is presently 36.21%.

Analyst Ratings Changes

STE has been the topic of a number of research reports. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Finally, Morgan Stanley lifted their price objective on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average target price of $273.50.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.